GlassScriptPhysician profile
Samantha R Debone
NPI 1356576987
$10,620.94
in general payments reported to CMS, 2019-2025
25 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,388 · 2022: $3,036 · 2023: $2,666 · 2024: $3,267 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,873 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,873.34 |
| Education | $324.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,043.59 | 2021-2024 | |
| Janssen Biotech, INC. | $1,819.54 | 2021-2025 | Tremfya, Simponi, Stelara |
| Amgen INC. | $808.13 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $759.69 | 2021-2025 | |
| Lilly USA, LLC | $669.61 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $570.09 | 2022-2024 | Sotyktu |
| Incyte Corporation | $505.02 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $479.58 | 2021-2024 | Adbry |
| Dermavant Sciences, INC. | $450.81 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $380.59 | 2022-2025 | Epsolay, Nemluvio |
| Novartis Pharmaceuticals Corporation | $352.16 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $327.39 | 2021-2024 | Blu-U, Odomzo, Winlevi |
| Pfizer INC. | $274.71 | 2021-2024 | |
| Journey Medical Corporation | $241.48 | 2022-2024 | |
| Ucb, INC. | $224.51 | 2022-2025 | Bimzelx, Cimzia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $157.25 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Regeneron Healthcare Solutions, INC. | $143.02 | 2021-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.57 | 2023-2024 | Spevigo |
| Epi Health, LLC | $82.36 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $79.03 | 2023 | |
| Verrica Pharmaceuticals INC. | $61.90 | 2023-2024 | Ycanth |
| Dermira, INC. | $38.75 | 2021 | |
| Nabriva Therapeutics, Plc | $18.83 | 2022 | |
| Mission Pharmacal Company | $14.91 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Debone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.